Neurocrine Biosciences, Inc. (NBIX)

NASDAQ • Healthcare

$143.18

+$2.46 (+1.8%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$141.41

Day Range$140.36 - $144.56

Avg. Volume (3M)1.3M

Market Cap$14.3B

P/E Ratio20.3

52 Week Range

$122.14$186.12

Next EarningsIn 23 daysOct 27, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$959M100%

Gross Profitminus cost of goods$935.8M98%

Operating Incomeminus R&D and overhead$153M16%

Net Incomeminus taxes and the rest$144.4M15%

In plain terms: out of every $100 in revenue, Neurocrine Biosciences, Inc. keeps $15 as net profit.

Fundamentals & Financials

Revenue (TTM)

$3.3B

Net Income (TTM)

$705.5M

EPS (TTM)

$7.05

ROA (TTM)

13.16%

Current Ratio

1.87

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+8.2%Q3 2025$1.06

+29.1%Q4 2025$2.04

+4.4%Q1 2026$1.88

+59.0%Q2 2026$1.94

-15.8%Q3 2026$1.39

Oct 27

in 23 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

Neurocrine Biosciences, Inc. (NBIX) reports next on October 27, 2026. Wall Street is looking for EPS of $2.59 on revenue of $1.04 billion. For trailing context, revenue was up +39.5% year over year last quarter. NBIX has beaten EPS in 4 of its 8 most recent quarters.

View full earnings history

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a biotechnology company listed on the NASDAQ Global Select Market under NBIX that develops and commercializes treatments for neurological, neuropsychiatric, and endocrine-related disorders. In FY2025, revenue was $2.9 billion, spanning commercial medicines and clinical-stage drug candidates.

Name

Neurocrine Biosciences, Inc.

CEO

Kyle W. Gano

Website

www.neurocrine.com

Industry

Healthcare

Year Founded

1992

Employees

2,500

Today's Snapshot

AI-generated

NBIX closed 1.8% higher at 143.18, while its sector was flat. Neurocrine Biosciences rehired former executives, changing its leadership team.

Trading Volume

Above 10d avg 1.5M

1.6M

vs S&P 500 Today

Outperforming Market

+0.98%

Updated: October 2, 2026 at 20:02 UTC

Technical Indicators

1 Buy3 Neutral4 Sell

Neurocrine Biosciences presents a cautious technical picture: price is slightly below most medium- and long-term averages and marginally above the classic pivot, while ADX near 29 suggests the downtrend has traction. Short-term averages are mixed-to-supportive and momentum indicators are muted, yet MACD and OBV lean negative, pointing to recent selling pressure. Volatility is moderate and the pivot provides a nearby reference for short-term trading. Technical takeaway: Sell bias driven by declining price versus medium-term averages and negative volume signals despite short-term support around the pivot.

All signals